cisapride has been researched along with Torsade de Pointes in 34 studies
Cisapride: A substituted benzamide used for its prokinetic properties. It is used in the management of gastroesophageal reflux disease, functional dyspepsia, and other disorders associated with impaired gastrointestinal motility. (Martindale The Extra Pharmacopoeia, 31st ed)
cisapride : The amide resulting from formal condensation of 4-amino-5-chloro-2-methoxybenzoic acid with cis-1-[3-(4-fluorophenoxy)propyl]-3-methoxypiperidin-4-amine. It has been used (as its monohydrate or as its tartrate) for the treatment of gastro-oesophageal reflux disease and for non-ulcer dyspepsia, but its propensity to cause cardiac arrhythmias resulted in its complete withdrawal from many countries, including the U.K., and restrictions on its use elsewhere.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In order to bridge the gap of information between the in silico model and human subjects, we evaluated torsadogenic risk of cisapride, dl-sotalol, bepridil and verapamil selected from 12 training compounds in the comprehensive in vitro proarrhythmia assay using the chronic atrioventricular block monkeys." | 8.02 | Torsadogenic Action of Cisapride, dl-Sotalol, Bepridil, and Verapamil Analyzed by the Chronic Atrioventricular Block Cynomolgus Monkeys: Comparison With That Reported in the CiPA In Silico Mechanistic Model. ( Goto, A; Izumi-Nakaseko, H; Kambayashi, R; Kanda, Y; Kawai, S; Matsumoto, A; Nunoi, Y; Sakamoto, K; Sugiyama, A; Takei, Y, 2021) |
| "Cisapride, a gastrointestinal prokinetic agent, was recently withdrawn from the market because of its propensity to induce torsade de pointes (TdP) arrhythmias." | 7.72 | Cisapride-induced transmural dispersion of repolarization and torsade de pointes in the canine left ventricular wedge preparation during epicardial stimulation. ( Antzelevitch, C; Belardinelli, L; Di Diego, JM, 2003) |
| "The FDA analyzed reports of patients who developed QT prolongation, torsades de pointes, and ventricular arrhythmia in association with the use of cisapride to assess probable etiology and risk factors." | 7.71 | Postmarketing reports of QT prolongation and ventricular arrhythmia in association with cisapride and Food and Drug Administration regulatory actions. ( Corken, A; Gallo-Torres, H; Rodriguez, EM; Talarico, L; Wysowski, DK, 2001) |
| "To highlight a case of torsade de pointes ventricular arrhythmia induced by the concomitant use of cisapride and clarithromycin." | 7.70 | Torsade de pointes induced by cisapride/clarithromycin interaction. ( Piquette, RK, 1999) |
| "In order to bridge the gap of information between the in silico model and human subjects, we evaluated torsadogenic risk of cisapride, dl-sotalol, bepridil and verapamil selected from 12 training compounds in the comprehensive in vitro proarrhythmia assay using the chronic atrioventricular block monkeys." | 4.02 | Torsadogenic Action of Cisapride, dl-Sotalol, Bepridil, and Verapamil Analyzed by the Chronic Atrioventricular Block Cynomolgus Monkeys: Comparison With That Reported in the CiPA In Silico Mechanistic Model. ( Goto, A; Izumi-Nakaseko, H; Kambayashi, R; Kanda, Y; Kawai, S; Matsumoto, A; Nunoi, Y; Sakamoto, K; Sugiyama, A; Takei, Y, 2021) |
| "The cardiac sodium channel (SCN5A) mutation L1825P has been identified in a patient with drug-induced torsade de pointes precipitated by the IKr blocker cisapride." | 3.73 | New mechanism contributing to drug-induced arrhythmia: rescue of a misprocessed LQT3 mutant. ( Liu, K; Roden, DM; Viswanathan, PC; Yang, T, 2005) |
| "The FDA analyzed reports of patients who developed QT prolongation, torsades de pointes, and ventricular arrhythmia in association with the use of cisapride to assess probable etiology and risk factors." | 3.71 | Postmarketing reports of QT prolongation and ventricular arrhythmia in association with cisapride and Food and Drug Administration regulatory actions. ( Corken, A; Gallo-Torres, H; Rodriguez, EM; Talarico, L; Wysowski, DK, 2001) |
| "To highlight a case of torsade de pointes ventricular arrhythmia induced by the concomitant use of cisapride and clarithromycin." | 3.70 | Torsade de pointes induced by cisapride/clarithromycin interaction. ( Piquette, RK, 1999) |
| "Drugs can cause cardiac arrhythmias in a number of clinical situations, and many of the implicated agents are used to treat non-cardiac conditions." | 2.40 | Drug-induced cardiac arrhythmias: incidence, prevention and management. ( Doig, JC, 1997) |
| " In responses to all three QT-lengthening compounds, RR, QT and QTc(F) lengthened similarly in a dose-response manner in both the failing and normal hearts." | 1.38 | Assessment of QT-prolonging drugs in the isolated normal and failing rabbit hearts. ( Hamlin, RL; Kijtawornrat, A; Sawangkoon, S, 2012) |
| "Erythromycin has shown QT prolongation and torsades de pointes (TdP) in humans and cisapride, a second class of prokinetic agents typified by the 5-HT(4) receptor agonist, has been terminated due to TdP." | 1.34 | Preclinical electrophysiology assays of mitemcinal (GM-611), a novel prokinetic agent derived from erythromycin. ( Itoh, M; Itoh, Z; Kato, A; Kimura, K; Mizoguchi, K; Omura, S; Suzuki, M; Tabo, M; Takanashi, H, 2007) |
| "Mitemcinal (GM-611) is a novel erythromycin-derived prokinetic agent that acts as an agonist at the motilin receptor." | 1.34 | Hemodynamic and electrophysiological effects of mitemcinal (GM-611), a novel prokinetic agent derived from erythromycin in a halothane-anesthetized canine model. ( Itoh, Z; Kato, A; Kimura, K; Mizoguchi, K; Omura, S; Suzuki, M; Tabo, M; Takanashi, H, 2007) |
| "Torsade de pointes is a rare but potentially fatal ventricular arrhythmia associated with drug-induced delayed repolarization and prolongation of the QT interval." | 1.31 | The canine Purkinje fiber: an in vitro model system for acquired long QT syndrome and drug-induced arrhythmogenesis. ( Cox, BF; Gintant, GA; Limberis, JT; McDermott, JS; Wegner, CD, 2001) |
| "Patients with chronic renal failure are often on multiple medications and are at risk for the development of adverse effects from drug interactions." | 1.30 | Torsades de pointes in two chronic renal failure patients treated with cisapride and clarithromycin. ( Sekkarie, MA, 1997) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 8 (23.53) | 18.2507 |
| 2000's | 19 (55.88) | 29.6817 |
| 2010's | 6 (17.65) | 24.3611 |
| 2020's | 1 (2.94) | 2.80 |
| Authors | Studies |
|---|---|
| Pearlstein, R | 1 |
| Vaz, R | 1 |
| Rampe, D | 1 |
| Mirams, GR | 1 |
| Cui, Y | 1 |
| Sher, A | 1 |
| Fink, M | 1 |
| Cooper, J | 1 |
| Heath, BM | 1 |
| McMahon, NC | 1 |
| Gavaghan, DJ | 1 |
| Noble, D | 1 |
| Wiśniowska, B | 1 |
| Mendyk, A | 1 |
| Fijorek, K | 1 |
| Glinka, A | 1 |
| Polak, S | 1 |
| Kramer, J | 1 |
| Obejero-Paz, CA | 1 |
| Myatt, G | 1 |
| Kuryshev, YA | 1 |
| Bruening-Wright, A | 1 |
| Verducci, JS | 1 |
| Brown, AM | 1 |
| Goto, A | 1 |
| Sakamoto, K | 1 |
| Kambayashi, R | 1 |
| Nunoi, Y | 1 |
| Izumi-Nakaseko, H | 1 |
| Kawai, S | 1 |
| Takei, Y | 1 |
| Matsumoto, A | 1 |
| Kanda, Y | 2 |
| Sugiyama, A | 3 |
| Yamamoto, W | 1 |
| Asakura, K | 1 |
| Ando, H | 1 |
| Taniguchi, T | 1 |
| Ojima, A | 1 |
| Uda, T | 1 |
| Osada, T | 1 |
| Hayashi, S | 1 |
| Kasai, C | 1 |
| Miyamoto, N | 1 |
| Tashibu, H | 1 |
| Yoshinaga, T | 1 |
| Yamazaki, D | 1 |
| Sawada, K | 1 |
| Sekino, Y | 1 |
| Vos, MA | 1 |
| Dabhi, J | 1 |
| Mehta, A | 1 |
| Collins, KK | 1 |
| Sondheimer, JM | 1 |
| Kijtawornrat, A | 2 |
| Sawangkoon, S | 1 |
| Hamlin, RL | 2 |
| Di Veroli, GY | 1 |
| Davies, MR | 1 |
| Zhang, H | 1 |
| Abi-Gerges, N | 1 |
| Boyett, MR | 1 |
| Di Diego, JM | 2 |
| Belardinelli, L | 1 |
| Antzelevitch, C | 2 |
| Buxeraud, J | 1 |
| Woroń, J | 1 |
| Trabka-Janik, E | 1 |
| Kostka-Trabka, E | 1 |
| Fish, JM | 1 |
| Nesterenko, V | 1 |
| Davie, C | 1 |
| Pierre-Valentin, J | 1 |
| Pollard, C | 1 |
| Standen, N | 1 |
| Mitcheson, J | 1 |
| Alexander, P | 1 |
| Thong, B | 1 |
| Al-Amood, S | 1 |
| Elming, H | 1 |
| Liu, K | 1 |
| Yang, T | 1 |
| Viswanathan, PC | 1 |
| Roden, DM | 2 |
| Nishijima, Y | 1 |
| Roche, BM | 1 |
| Keene, BW | 1 |
| Kimura, K | 2 |
| Tabo, M | 2 |
| Itoh, M | 1 |
| Mizoguchi, K | 2 |
| Kato, A | 2 |
| Suzuki, M | 2 |
| Itoh, Z | 2 |
| Omura, S | 2 |
| Takanashi, H | 2 |
| Wysowski, DK | 2 |
| Bacsanyi, J | 1 |
| Puisieux, FL | 1 |
| Adamantidis, MM | 1 |
| Dumotier, BM | 1 |
| Dupuis, BA | 1 |
| Sekkarie, MA | 1 |
| Doig, JC | 1 |
| Vitola, J | 1 |
| Vukanovic, J | 1 |
| Kantoch, MJ | 1 |
| Qurashi, MM | 1 |
| Bulbul, ZR | 1 |
| Gorgels, AP | 1 |
| Piquette, RK | 1 |
| Chen, YJ | 1 |
| Lee, SH | 1 |
| Hsieh, MH | 1 |
| Hsiao, CJ | 1 |
| Yu, WC | 1 |
| Chiou, CW | 1 |
| Chen, SA | 1 |
| Ng, KS | 1 |
| Tham, LS | 1 |
| Tan, HH | 1 |
| Chia, BL | 1 |
| Gintant, GA | 1 |
| Limberis, JT | 1 |
| McDermott, JS | 1 |
| Wegner, CD | 1 |
| Cox, BF | 1 |
| Corken, A | 1 |
| Gallo-Torres, H | 1 |
| Talarico, L | 1 |
| Rodriguez, EM | 1 |
| Sugiyam, A | 1 |
| Ishida, Y | 1 |
| Satoh, Y | 1 |
| Aoki, S | 1 |
| Hori, M | 1 |
| Akie, Y | 1 |
| Kobayashi, Y | 1 |
| Hashimoto, K | 1 |
5 reviews available for cisapride and Torsade de Pointes
| Article | Year |
|---|---|
Understanding the structure-activity relationship of the human ether-a-go-go-related gene cardiac K+ channel. A model for bad behavior.
Topics: Cation Transport Proteins; DNA-Binding Proteins; Drug-Related Side Effects and Adverse Reactions; ER | 2003 |
Literature-based evaluation of four 'hard endpoint' models for assessing drug-induced torsades de pointes liability.
Topics: Animals; Aza Compounds; Cisapride; Dogs; Drug Evaluation, Preclinical; Drug-Related Side Effects and | 2008 |
[Effects of clinically available drugs on the repolarization process of the heart assessed by the in vivo canine models].
Topics: Action Potentials; Animals; Anti-Arrhythmia Agents; Antipsychotic Agents; Antitubercular Agents; Cat | 2003 |
[Side effects, unwanted drug interactions and the problem of cardiotoxicity].
Topics: Cisapride; Drug Interactions; Fluoroquinolones; Histamine H1 Antagonists; Humans; Long QT Syndrome; | 2003 |
Drug-induced cardiac arrhythmias: incidence, prevention and management.
Topics: Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhythmia Agents; Anti-Infective Agents; | 1997 |
29 other studies available for cisapride and Torsade de Pointes
| Article | Year |
|---|---|
Simulation of multiple ion channel block provides improved early prediction of compounds' clinical torsadogenic risk.
Topics: Action Potentials; Animals; Calcium Channel Blockers; Calcium Channels, L-Type; Computer Simulation; | 2011 |
Predictive model for L-type channel inhibition: multichannel block in QT prolongation risk assessment.
Topics: Artificial Intelligence; Calcium Channel Blockers; Calcium Channels, L-Type; Cell Line; Computationa | 2012 |
MICE models: superior to the HERG model in predicting Torsade de Pointes.
Topics: ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Humans; Models, Theoretical; Patch-Clamp T | 2013 |
Torsadogenic Action of Cisapride, dl-Sotalol, Bepridil, and Verapamil Analyzed by the Chronic Atrioventricular Block Cynomolgus Monkeys: Comparison With That Reported in the CiPA In Silico Mechanistic Model.
Topics: Animals; Atrioventricular Block; Bepridil; Cisapride; Computer Simulation; Macaca fascicularis; Sota | 2021 |
Electrophysiological Characteristics of Human iPSC-Derived Cardiomyocytes for the Assessment of Drug-Induced Proarrhythmic Potential.
Topics: Cells, Cultured; Chromans; Cisapride; Electrophysiological Phenomena; Heart Rate; Humans; Induced Pl | 2016 |
QT prolongation and safety in the Indian population.
Topics: Astemizole; Cisapride; Databases, Factual; Drug-Related Side Effects and Adverse Reactions; Electroc | 2007 |
Domperidone-induced QT prolongation: add another drug to the list.
Topics: Animals; Cisapride; Domperidone; Dopamine Antagonists; Drug-Related Side Effects and Adverse Reactio | 2008 |
Assessment of QT-prolonging drugs in the isolated normal and failing rabbit hearts.
Topics: Animals; Arrhythmias, Cardiac; Cisapride; Electrocardiography; Feasibility Studies; Glucose; Heart; | 2012 |
High-throughput screening of drug-binding dynamics to HERG improves early drug safety assessment.
Topics: Action Potentials; Animals; CHO Cells; Cisapride; Computer Simulation; Cricetinae; Cricetulus; Dogs; | 2013 |
Cisapride-induced transmural dispersion of repolarization and torsade de pointes in the canine left ventricular wedge preparation during epicardial stimulation.
Topics: Animals; Cisapride; Dogs; Dose-Response Relationship, Drug; Electric Stimulation; Electrocardiograph | 2003 |
[New conditions for prescribing Prepulsid].
Topics: Anti-Ulcer Agents; Cisapride; Contraindications; Electrocardiography; Gastrointestinal Motility; Hum | 2003 |
Epicardial activation of left ventricular wall prolongs QT interval and transmural dispersion of repolarization: implications for biventricular pacing.
Topics: Action Potentials; Animals; Anti-Arrhythmia Agents; Cardiac Pacing, Artificial; Cisapride; Computer | 2004 |
Comparative pharmacology of guinea pig cardiac myocyte and cloned hERG (I(Kr)) channel.
Topics: Animals; Cation Transport Proteins; Cisapride; Dose-Response Relationship, Drug; Electrophysiologic | 2004 |
[Cardiac arrest following treatment with non-cardiologic QT-interval-increasing medications].
Topics: Bendroflumethiazide; Butyrophenones; Cisapride; Diuretics; Electrocardiography; Female; Furosemide; | 2005 |
New mechanism contributing to drug-induced arrhythmia: rescue of a misprocessed LQT3 mutant.
Topics: Action Potentials; Animals; CHO Cells; Cisapride; Cricetinae; Humans; Ion Channel Gating; Long QT Sy | 2005 |
Use of a failing rabbit heart as a model to predict torsadogenicity.
Topics: Amiodarone; Animals; Cardiac Output, Low; Cisapride; Dose-Response Relationship, Drug; Electrocardio | 2006 |
Preclinical electrophysiology assays of mitemcinal (GM-611), a novel prokinetic agent derived from erythromycin.
Topics: Action Potentials; Animals; Cell Line; Cisapride; Dose-Response Relationship, Drug; Drug Evaluation, | 2007 |
Hemodynamic and electrophysiological effects of mitemcinal (GM-611), a novel prokinetic agent derived from erythromycin in a halothane-anesthetized canine model.
Topics: Action Potentials; Anesthesia, General; Anesthetics, Inhalation; Animals; Blood Pressure; Cardiac Pa | 2007 |
Cisapride and fatal arrhythmia.
Topics: Anti-Bacterial Agents; Antifungal Agents; Cisapride; Drug Interactions; Drug Labeling; Humans; Imida | 1996 |
Cisapride-induced prolongation of cardiac action potential and early afterdepolarizations in rabbit Purkinje fibres.
Topics: Action Potentials; Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Cisapride; Electrophysiolo | 1996 |
Torsades de pointes in two chronic renal failure patients treated with cisapride and clarithromycin.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Cisapride; Clarithromycin; Drug Interactions; Female | 1997 |
Cisapride-induced torsades de pointes.
Topics: Adolescent; Anti-Bacterial Agents; Biotransformation; Cisapride; Electrocardiography; Female; Follow | 1998 |
A newborn with a complex congenital heart disease, atrioventricular block, and torsade de pointes ventricular tachycardia.
Topics: Cisapride; Electrocardiography; Female; Heart Block; Heart Defects, Congenital; Humans; Infant, Newb | 1998 |
Torsade de pointes induced by cisapride/clarithromycin interaction.
Topics: Aged; Anti-Bacterial Agents; Cisapride; Clarithromycin; Cytochrome P-450 CYP3A; Cytochrome P-450 Enz | 1999 |
Effects of 17beta-estradiol on tachycardia-induced changes of atrial refractoriness and cisapride-induced ventricular arrhythmia.
Topics: Action Potentials; Animals; Anti-Arrhythmia Agents; Cisapride; Disease Models, Animal; Dogs; Dose-Re | 1999 |
Cisapride and torsades de pointes in a pacemaker patient.
Topics: Aged; Aged, 80 and over; Cardiac Pacing, Artificial; Cisapride; Dementia; Electrocardiography; Femal | 2000 |
The canine Purkinje fiber: an in vitro model system for acquired long QT syndrome and drug-induced arrhythmogenesis.
Topics: Action Potentials; Animals; Anti-Infective Agents; Arrhythmias, Cardiac; Aza Compounds; Cisapride; D | 2001 |
Postmarketing reports of QT prolongation and ventricular arrhythmia in association with cisapride and Food and Drug Administration regulatory actions.
Topics: Adverse Drug Reaction Reporting Systems; Arrhythmias, Cardiac; Cisapride; Contraindications; Drug an | 2001 |
Electrophysiological, anatomical and histological remodeling of the heart to AV block enhances susceptibility to arrhythmogenic effects of QT-prolonging drugs.
Topics: Animals; Arrhythmias, Cardiac; Atrioventricular Node; Blood Pressure; Body Weight; Cisapride; Dogs; | 2002 |